Albumin Infusion for Decompensated Cirrhosis (ATTIRE trial), Terlipressin for Type 1 Hepatorenal Syndrome (CONFIRM trial)

Last Week in Medicine

English - March 11, 2021 00:00 - 39 minutes - 26.8 MB - ★★★★★ - 40 ratings
Medicine Health & Fitness internal medicine medical journals research articles guidelines Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: IL-6 Receptor Antagonists Reduce Mortality in Critically Ill COVID-19 Patients (REMAP-CAP, RECOVERY), Convalescent Plasma Fails to Improve Mortality

Next Episode: Weekly Semaglutide for Weight Loss (STEP 1, 2 and 3 Trials), 4PEPS Rule for Pulmonary Embolism, Nafcillin vs Cefazolin for Epidural Abscess, Ferritin/Procalcitonin Ratio for COVID19, Intermediate Thromboprophylaxis for COVID19

Today has a nice liver disease theme. Does targeting a serum albumin above 3 g/dL reduce death, infections and kidney failure in patients with decompensated cirrhosis? Does terlipressin work in hepatorenal syndrome?

Albumin Infusion for Decompensated Cirrhosis
Terlipressin for Type 1 Hepatorenal Syndrome

Music from https://filmmusic.io
"Sneaky Snitch" by Kevin MacLeod (https://incompetech.com)
License: CC BY (http://creativecommons.org/licenses/by/4.0/)